Search

Displaying results 5371 - 5380 of 10000 in total
  1. Drug

    EC-0652

    go.drugbank.com/drugs/DB15340
    Experimental

    EC-0652 is under investigation in clinical trial NCT02202447 (Phase 1 of EC1169 In Patients With Recurrent MCRPC).

  2. Drug

    Candida albicans

    go.drugbank.com/drugs/DB10429
    ApprovedInvestigational

    Candida albicans is used in allergenic testing.

  3. Drug

    Saccharomyces cerevisiae

    go.drugbank.com/drugs/DB10447
    Approved

    Saccharomyces cerevisiae is used in allergenic testing.

    Mixtures: B Complex
  4. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  5. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  6. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    Ranpirnase is a ribonuclease enzyme found in <i>Rana pipiens</i> oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation.

  7. Drug

    AM365

    go.drugbank.com/drugs/DB06564
    Experimental

    Detiviciclovir (AM365) is an antiviral nucleoside analogue.

  8. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

  9. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  10. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.